Premium
Enhanced killing of human small cell lung cancer by hyperthermia and lndium‐111‐ bleomycin complex
Author(s) -
Hou DeYan,
Maruyama And Yosh
Publication year - 1990
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930440103
Subject(s) - bleomycin , hyperthermia , medicine , in vivo , cancer research , cell , lung cancer , in vitro , cancer cell , cancer , pathology , chemotherapy , biology , biochemistry , microbiology and biotechnology
Indium‐111‐bleomycin complex ( 111 In‐BLMC) is a radiopharmaceutical agent that produces tumor regression in mouse glioma in vivo and kills human small cell lung cancer (SCLC) cells in vitro. The interaction between hyperthermia and 111 In‐BLMC against human SCLC (N417) cells was studied for bleomycin (BLM) (15 μ/ml) or 111 In‐BLMC (40–50 μCi carried by 15 μg BLM/ml) for 5 min or 1.5, 2, or 4 hr at 37°C or 43°C exposures. Cell survival was determined by colony formation in soft aga‐rose. There was a synergistic effect for 111 In‐BLMC and hyperthermia for cell killing. At 37°C, the percent survival of N417 cells for BLM alone was 25.9%, and for 111 In‐BLMC it was 13.2%; at 43°C, survival was 5.3% for BLM alone and 1.2% for 111 In‐BLMC by a 4 hr treatment. Effectiveness was greater when 111 In‐BLMC was combined with hyperthermia.